Could a daily pill offer Australians another way to manage weight without injections? Two oral medicines have recently received regulatory approval, bringing new options into a treatment area where weekly injections have attracted considerable attention.
Australia’s Therapeutic Goods Administration (TGA) registered Foundayo, containing orforglipron, on 16 November 2026. Earlier in November, the regulator approved a tablet form of Wegovy, which contains semaglutide. The medicines are different, and approval does not mean that either is suitable for everyone.
What is Foundayo?
Foundayo is an oral medicine made by Eli Lilly. Its active ingredient, orforglipron, acts on GLP-1 receptors involved in regulating appetite and other functions. Australian reporting on 17 November said the medicine had been cleared for weight management and type 2 diabetes.
The TGA’s public register lists several strengths. The manufacturer expected supplies to reach Australia in the coming days, according to contemporary reporting. Availability at a particular pharmacy may differ, and a prescription is required.
How does the Wegovy tablet compare?
Wegovy contains semaglutide, a different GLP-1 medicine. The TGA approved its tablet form for adults for chronic weight management alongside a reduced-energy diet and increased physical activity. The regulator also approved its use alongside standard care to reduce the risk of major cardiovascular events in people with established cardiovascular disease, under the approved conditions.
The TGA decision was made on 2 November, with registration on 3 November. Approval establishes that a medicine can be registered for its authorised uses; the timing of actual supply is a separate matter.
Although both medicines act on GLP-1 receptors, their ingredients and instructions differ. They should not be treated as interchangeable without a clinician’s advice. The presence of a tablet option also does not by itself establish that it is more effective or safer than an injection for an individual patient.
Who might be eligible?
These are prescription medicines for specific medical circumstances. Eligibility depends on the approved product information and a clinician’s assessment, including a person’s health history, other medicines and treatment goals.
Weight-management medicines are generally considered as part of longer-term care rather than a quick cosmetic solution. A doctor can explain whether a treatment is appropriate and how progress and side effects would be monitored.
What about side effects and cost?
Digestive side effects can occur with GLP-1 medicines. Australian reporting on Foundayo noted that its manufacturer warned against using it with other GLP-1 medicines and identified additional precautions, including pregnancy and possible medicine interactions. Patients should discuss their individual risks and the approved product information with a healthcare professional.
Actual out-of-pocket costs depend on the prescription, pharmacy and any applicable subsidy. Approval and registration do not automatically establish a subsidised price or immediate nationwide stock.
What happens next?
The new approvals expand the range of oral weight-management treatments in Australia, with Foundayo’s registration following the earlier Wegovy tablet decision. For people considering either medicine, the practical next step is to discuss eligibility, safety, availability and cost with a qualified clinician or pharmacist.